A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy

10 January 2001

journal article
Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section

Vol. 108 (1) , 71-77
https://doi.org/10.1007/s007020170098

Abstract

Objective. To determine if therapy with an ergot and a non-ergot dopamine agonist and levodopa confers an increased risk of excessive daytime sleepiness and secondary "sleep attacks" in Parkinson's disease (PD). Methods. Comparative study of three clinical groups taking, pramipexole (Group 1, n = 19, 8 monotherapy), cabergoline (Group 2, n = 22, 10 monotherapy), and levodopa monotherapy (Group 3, n = 14). Clinical and demographic characteristics, occurrence of "sleep attacks", and assessment of daytime sleepiness [using the Epworth Sleepiness Scale (ESS)], recorded. Results. No patients reported "sleep attacks". Mean ESS scores: Group 1 (pramipexole) 8.0 ± 4.5 (range 0–16), Group 2 (cabergoline) 8.1 ± 3.9 (range 0–19), Group 3 (levodopa), 8.1 ± 5.5 (range 1–18). There was no significant difference between groups (p = 0.897). Scores of ≥16 indicating excessive daytime sleepiness (EDS) were evenly distributed throughout treatment groups, particularly in older patients with more advanced disease. Conclusions.

Keywords

This publication has 0 references indexed in Scilit: